Patiromer and MRA Doses in Patients With Current or Past Hyperkalemia
Autores da FMUP
Unidades de investigação
Abstract
[No abstract available]
Dados da publicação
- ISSN/ISSNe:
- 2213-1787, 2213-1779
- Tipo:
- Editorial Material
- Páginas:
- 2038-2040
- Link para outro recurso:
- www.scopus.com
JACC-HEART FAILURE Elsevier BV
Documentos
- Não há documentos
Filiações
Keywords
- eplerenone; mineralocorticoid antagonist; patiromer; spironolactone; patiromer; drug dose increase; drug dose titration; Editorial; estimated glomerular filtration rate; heart failure with reduced ejection fraction; hospitalization; human; hyperkalemia; mortality; potassium blood level; potassium excretion; randomized controlled trial (topic); editorial; hyperkalemia; titrimetry
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023
Citar a publicação
Ferreira JP. Patiromer and MRA Doses in Patients With Current or Past Hyperkalemia. JACC Heart Fail. 2024. 12(12):p. 2038-2040. IF:13,000. (1).